The DOI matches its Crossref record; 283 of the 283 references it cites were found in a registry or an index.
Inflammation as a central mechanism in Alzheimer's disease
Open accessAbstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the brain's resident macrophages (microglia) and other immune cells has been demonstrated to exacerbate both amyloid and tau pathology and may serve as a link in the pathogenesis of the disorder. In the following review, we provide an overview of inflammation in AD and a detailed coverage of a number of microglia‐related signaling mechanisms that have been implicated in AD. Additional information on microglia signaling and a number of cytokines in AD are also reviewed. We also review the potential connection of risk factors for AD and how they may be related to inflammatory mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous cytokines and chemokines have been shown to contribute to the pathogenesis of neurodegenerative diseases as summarized by the recent reviews.9,253,412”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This immune response in turn activates glia and induces the secretion of pro-inflammatory cytokines, which can drive further aggregation of Aβ by affecting the capacity of microglia and astrocytes for phagocytosis and degradation [26].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic microglial inflammation has been observed in the brains of AD patients at various disease stages, and pro-inflammatory cytokines such as IL-1β, IL-2, IL-6, and tumor necrosis factor-α have been shown to be upregulated in AD [35].”
From Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ levels are generally well-correlated with immune activation indicated by microgliosis and astrocytosis [3].”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, the innate immune system activation, in particular microglia, is considered a contributing factor to AD pathogenesis rather than a consequence of pathology 2 .”
From ABI3 deletion in TgCRND8 mice is associated with reduced amyloid plaque pathology and altered glial response (2023) · cites this paper as [2]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Theses neuroinflammatory responses are considered a major driving factor in patients with neurodegeneration and Alzheimer’s disease pathology, which starts early in the course of the disease, prior to the formation of Aβ plaques in the brain73.”
From Chlamydia pneumoniae can infect the central nervous system via the olfactory and trigeminal nerves and contributes to Alzheimer’s disease risk (2022) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the comparison between B6 and 5xFAD mice, the concentrations of two proinflammatory cytokines, interleukin-1 β (IL-1B), tumor necrosis factor-alpha (TNFα ), were increased Figure 3G), and those of two other cytokines, IL-10, IL-5, were decreased (Figure 3H), consistent with previous findings 30 .”
From Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer’s disease (2023) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Prolonged microglial activation may be detrimental, since it eventually leads to a self-perpetuating cycle involving the production of neurotoxic pro-inflammatory cytokines, damaging neurons, inducing more recruitment of microglia, further increasing their activation and release of pro-inflammatory cytokines [35].”
From Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“Neuroinflammation is also linked to neurodegeneration and neuronal loss, which are features that coincidently are associated with amyloid plaque formation (DeTure and Dickson, 2019; Kinney et al., 2018; Sung et al., 2020).”
From Arbovirus infection increases the risk for the development of neurodegenerative disease pathology in the murine model (2024) · cites this paper as Kinney et al., 2018
In the citing paper
“Due to the dysregulation of GABAergic mechanism in AD, the inhibitory role of GABA on activated microglia is also lost which further contributes to the release of pro-inflammatory cytokines [17].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [17]
In the citing paper
“The chronic, sustained inflammatory response in the brain is considered the third core pathological feature of AD.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [84]
In the citing paper
“This chronic neuroinflammation is caused by persistent activation of glial cells and excessive release of cytotoxic molecules, which adversely affects brain function and is a major cofactor in the pathogenesis of many neurodegenerative disorders, including AD [84].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [84]
In the citing paper
“It provides a link between the other two core pathologies, Aβ plaques and NFTs [84].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [84]
In the citing paper
“Continuous activation of the brain’s immune cells, such as microglia, leads to the release and production of various proinflammatory cytokines, which aids tau and Aβ pathologies and leads to the loss of neurons [24].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 2×
“[144] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.”
BackgroundGlutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518 · cited 2×
“[261] Hotamisligil GS, Shargill NS, Spiegelman BM.”
BackgroundA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913 · cited 2×
“Overall surveillance of the surrounding neuronal environment is accomplished via a large number of signaling mechanisms [99,102].”
BackgroundAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580 · cited 1×
“[75] Glass CK, Saijo K,Winner B, Marchetto MC, Gage FH.”
BackgroundApolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“regulation of lipid transport, and aid of injury repair within the brain, ApoE plays a role in glucose metabolism [276,277].”
BackgroundThe pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 2×
“Pro-inflammatory signaling: IL-6 IL-6 is an important, multifunctional cytokine that can be considered proinflammatory or anti-inflammatory depending on the amount and condition in which it was released [209].”
BackgroundA protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089 · cited 1×
“[27] Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW.”
BackgroundImmunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 2×
“[133] Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al.”
BackgroundWeıntraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 3,018
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642 · cited 2×
“[2] Hebert LE, Weuve J, Scherr PA, Evans DA.”
BackgroundJung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632 · cited 3×
“[174] Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al.”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“the R47H variant of TREM2 and late-onset AD [133,136].”
BackgroundRisk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187 · cited 1×
“[246] Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P.”
BackgroundDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 1×
“The function of APP is unknown but is believed to have a role in cell health and growth [5].”
BackgroundNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“[38] Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ,”
BackgroundA new class of membrane-bound chemokine with a CX3C motif
Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., & Schall, T. J. (1997) · Nature · doi:10.1038/385640a0 · Cited by 2,013 · cited 2×
“[159] Bazan JF, Bacon KB, Hardiman G, WangW, Soo K, Rossi D, et al.”
BackgroundBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 2×
“[114] Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al.”
BackgroundThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 2×
“Since the 1980s, there have been reports of immune-related proteins and cells located within close proximity to b-amyloid plaques [43,84].”
BackgroundAlzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 2×
“[256] Steen E, Terry BM, J Rivera E, Cannon JL, Neely TR, Tavares R, et al.”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 2×
“[237] Kivipelto M1, Helkala EL, Laakso MP, H€anninen T, Hallikainen M,”
BackgroundControl of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531 · cited 3×
“[165] Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al.”
BackgroundThe microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511 · cited 2×
“[168] Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang L-C, Means TK, et al.”
BackgroundImai, T., Hieshima, K., Haskell, C. A., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T. J., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80438-9 · Cited by 1,472 · cited 2×
“[170] Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al.”
BackgroundProduction of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“[15] Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al.”
BackgroundInflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355 · cited 1×
“[73] Amor S, Puentes F, Baker D, van der Valk P.”
BackgroundMicroglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Simard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265 · cited 1×
“[115] Simard AR, Soulet D, Gowing G, Julien J-P, Rivest S.”
BackgroundTREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 2×
“[236] Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, et al.”
BackgroundHayden, M. S., West, A. P., & Ghosh, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209943 · Cited by 1,178
Harrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K., Streit, W. J., Salafranca, M. N., Adhikari, S., Thompson, D. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10896 · Cited by 1,176 · cited 3×
“This includes surveillance of the local neuronal milieu via numerous receptors for classical neurotransmitters [103], receptors for numerous cytokines and chemokines [104–106], and a number of receptors, such as fractalkine (CX3CR1), that bind ligands constitutively released in healthy neuronal environments [107].”
BackgroundRole of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
Tau in Alzheimer Disease and Related Tauopathies
Iqbal, K., Liu, F., Gong, C., & Grundke, I. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611592 · Cited by 1,163 · cited 2×
“In addition, the hyperphosphorylated tau (ptau) aggregates into paired helical fragments that eventually form neurofibrillary tangles [20,24,25,32,33].”
BackgroundMicroglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127 · cited 1×
“Microglia are primed in AD brains to be more susceptible to secondary inflammatory insults, resulting in an exacerbated inflammatory response [273].”
BackgroundA Meta-Analysis of Cytokines in Alzheimer's Disease
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108 · cited 2×
“[267] Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J,”
BackgroundRole of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005 · cited 2×
“remove tau from microtubules, allowing transport, followed by dephosphorylation to return tau to the microtubule [28].”
BackgroundRoles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Role of neuroinflammation in neurodegenerative diseases (Review)
Chen, W., Zhang, X., & Huang, W. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4948 · Cited by 961
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 1×
“[245] Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC.”
Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease
Mosconi, L. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1762-7 · Cited by 938
Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias
Plassman, B. L., Havlik, R. J., Steffens, D. C., Helms, M. J., Newman, T. N., Drosdick, D., Phillips, C., Gau, B. A., Welsh–Bohmer, K. A., Burke, J. R., et al. (2000) · Neurology · doi:10.1212/wnl.55.8.1158 · Cited by 896 · cited 2×
“In deceased patients suffering from recent head trauma, there is an increase in cerebral Ab deposits 1–3 weeks postinjury, and it has been shown that elevated levels of interleukin 1 (IL-1) are responsible for the increased APP production and Ab load [93,94].”
BackgroundNeuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
(2016) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 874
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/756357 · Cited by 864
Alonso, A. D. C., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0796-783 · Cited by 859 · cited 1×
“[18] Alonso AC, Grundke-Iqbal I, Iqbal K.”
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840 · cited 3×
“[151] Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, et al.”
BackgroundNormal and Abnormal Biology of the Beta-Amyloid Precursor Protein
Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 834 · cited 1×
“Ab pathology arises from the improper cleavage of the amyloid precursor protein (APP) resulting in Ab monomers that aggregate forming oligomeric Ab and eventually aggregating into Ab fibrils and plaques [4].”
BackgroundEbneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., Mandelkow, E.-M., & Mandelkow, E. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.3.777 · Cited by 820 · cited 1×
“[29] Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B,”
BackgroundBancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease
Jo, S., Yarishkin, O., Hwang, Y. J., Chun, Y. E., Park, M., Woo, D. H., Bae, J. Y., Kim, T., Lee, J., Chun, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3639 · Cited by 783 · cited 1×
“[181] Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al.”
BackgroundKöpke, E., Tung, Y. C., Shaikh, S., Alonso, A. C., Iqbal, K., & Grundke-Iqbal, I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80536-5 · Cited by 779
Passage of cytokines across the blood–brain barrier
Banks, W. A., Kastin, A. J., & Broadwell, R. D. (1996) · Neuroimmunomodulation · doi:10.1159/000097202 · Cited by 778 · cited 2×
“[269] Banks WA, Kastin AJ, Broadwell RD.”
BackgroundRogers, J., Luber-Narod, J., Styren, S. D., & Civin, W. H. (1988) · Neurobiology of Aging · doi:10.1016/s0197-4580(88)80079-4 · Cited by 743 · cited 2×
“Since the 1980s, there have been reports of immune-related proteins and cells located within close proximity to b-amyloid plaques [43,84].”
BackgroundRole of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease.
Alonso, A. C., Zaidi, T., Grundke-Iqbal, I., & Iqbal, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5562 · Cited by 738 · cited 1×
“[19] Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K.”
DEFECTIVE BRAIN MICROTUBULE ASSEMBLY IN ALZHEIMER'S DISEASE
Iqbal, K., Zaidi, T., Wen, G. Y., Grundke, I., MERZ, P. A., Shaikh, S., Wisniewski, H., Alafuzoff, I. I., & Winblad, B. G. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92134-3 · Cited by 737 · cited 1×
“[23] Iqbal K, Zaidi T, Wen G, Grundke-Iqbal I, Merz P, Shaikh S, et al.”
BackgroundThe role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Šimić, G., Leko, M. B., Wray, S., Harrington, C. R., Delalle, I., Milošević, N. J., Bažadona, D., Buée, L., de Silva, R., Giovanni, G. D., et al. (2016) · Biomolecules · doi:10.3390/biom6010006 · Cited by 730
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 2×
“[255] Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, la Monte de SM.”
BackgroundCombs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721
Fleminger, S. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.7.857 · Cited by 719 · cited 1×
“[239] Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A.”
Chen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 698
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697 · cited 1×
“[79] Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM.”
BackgroundPaloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683 · cited 1×
“[138] Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al.”
BackgroundJay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682
Self-citationThe contribution of astrocytes and microglia to traumatic brain injury
Karve, I. P., Taylor, J. M., & Crack, P. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13125 · Cited by 675
Gong, C., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 673
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657
Kim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655 · cited 1×
“Brain inflammation appears to have a dual function, playing a neuroprotective role during an acute-phase response, but becomes detrimental when a chronic response is mounted [92].”
BackgroundRhein, V., Song, X., Wiesner, A., Ittner, L. M., Baysang, G., Meier, F., Ozmen, L., Bluethmann, H., Dröse, S., Brandt, U., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905529106 · Cited by 655
Neurotransmitter receptors on microglia
Pocock, J. M., & Kettenmann, H. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.07.007 · Cited by 650
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643
Regulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639 · cited 2×
“[175] Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT.”
BackgroundSelf-citationNSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Brain fuel metabolism, aging, and Alzheimer’s disease
Cunnane, S. C., Nugent, S., Roy, M., Courchesne‐Loyer, A., Croteau, É., Tremblay, S., Castellano, A., Pifferi, F., Bocti, C., Paquet, N., et al. (2010) · Nutrition · doi:10.1016/j.nut.2010.07.021 · Cited by 633 · cited 1×
“[243] Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E,”
Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
Barger, S. W., & Harmon, A. D. (1997) · Nature · doi:10.1038/42257 · Cited by 622 · cited 1×
“The ability of IL-1b to increase Ab burden and plaque deposition creates a self-sustaining cycle wherein the increase of Ab load results in further microglia activation and IL-1b production [207,208].”
BackgroundKaltschmidt, B., Uherek, M., Volk, B., Baeuerle, P. A., & Kaltschmidt, C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2642 · Cited by 619
Sphingolipid-modulated Exosome Secretion Promotes Clearance of Amyloid-β by Microglia
Yuyama, K., Sun, H., Mitsutake, S., & Igarashi, Y. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.324616 · Cited by 612
Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells.
Goldgaber, D., Harris, H. W., Hla, T., Maciag, T., DONNELLY, R. J., Jacobsen, J. S., Vitek, M. P., & Gajdusek, D. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7606 · Cited by 597 · cited 2×
“[93] Goldgaber D, Harris HW, Hla T,Maciag T, Donnelly RJ, Jacobsen JS, et al.”
BackgroundMortimer, J. A., Van Duijn, C. M., Chandra, V, Fratiglioni, L., Graves, A. B., Heyman, A., Jorm, A. F., Kokmen, E., Kondo, K., Rocca, W. A., et al. (1991) · International Journal of Epidemiology · doi:10.1093/ije/20.supplement_2.s28 · Cited by 594 · cited 1×
“[238] Mortimer JA, Van Duiin CM, Chandra V, Fratiglioni L, Graves AB,”
BackgroundNeurofibrillary Tangles, Amyloid, and Memory in Aging and Mild Cognitive Impairment
Guillozet-Bongaarts, A. L., Weıntraub, S., Mash, D. C., & Mesulam, M. M. (2003) · Archives of Neurology · doi:10.1001/archneur.60.5.729 · Cited by 590
Murine tumor necrosis factor alpha is transported from blood to brain in the mouse
Gutierrez, E. G., Banks, W. A., & Kastin, A. J. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90027-v · Cited by 577 · cited 2×
“Whether the peripheral inflammation is arising from adiposity or another source, proinflammatory cytokines can cross the blood-brain barrier, which triggers brain-specific inflammatory responses [268,269].”
BackgroundGeneration of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells.
Busciglio, J., Gabuzda, D. H., Matsudaira, P., & Yankner, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.2092 · Cited by 569 · cited 1×
“[8] Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA.”
BackgroundInverse association of anti‐inflammatory treatments and Alzheimer's disease
Breitner, J. C. S., Gau, B. A., Welsh-Bohmer, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 569 · cited 1×
“[86] Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, et al.”
BackgroundBuxbaum, J. D., Oishi, M., Chen, H. I., Pinkas‐Kramarski, R., JAFFE, E. A., Gandy, S., & Greengard, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10075 · Cited by 563 · cited 2×
“[206] Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA,”
BackgroundAmyloid-Beta: A Crucial Factor in Alzheimer's Disease
Sadigh‐Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., & Mahmoudi, J. (2014) · Medical Principles and Practice · doi:10.1159/000369101 · Cited by 563 · cited 1×
“[13] Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J.”
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease
Fuhrmann, M., Bittner, T., Jung, C. K. E., Burgold, S., Page, R. M., Mitteregger, G., Haass, C., LaFerla, F. M., Kretzschmar, H., & Herms, J. (2010) · Nature Neuroscience · doi:10.1038/nn.2511 · Cited by 562 · cited 2×
“[166] Fuhrmann M, Bittner T, Jung CKE, Burgold S, Page RM, Mitteregger G, et al.”
BackgroundInflammation in neurodegenerative diseases—An update
Amor, S., Peferoen, L. A. N., Vogel, D. Y. S., Breur, M., van der Valk, P., Baker, D., & van Noort, J. M. (2014) · Immunology · doi:10.1111/imm.12233 · Cited by 550 · cited 1×
“[72] Amor S, Peferoen LAN, Vogel DYS, Breur M, Valk P, Baker D, et al.”
BackgroundInterleukin-1 Expression in Different Plaque Types in Alzheimerʼs Disease
Griffin, W. S. T., Sheng, J. G., Roberts, G. W., & Mrak, R. E. (1995) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199503000-00014 · Cited by 546
Ma, Q.-L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., Chen, P. P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1071-09.2009 · Cited by 536
Butterfield, D. A., Swomley, A. M., & Sultana, R. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5027 · Cited by 526
Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance
Bolmont, T., Haiss, F., Eicke, D., Radde, R., Mathis, C. A., Klunk, W. E., Kohsaka, S., Jucker, M., & Calhoun, M. E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4814-07.2008 · Cited by 526 · cited 2×
“Activated microglia respond to Ab resulting in migration to the plaques and phagocytosis of Ab [108,112,113].”
BackgroundTREM2 sustains microglial expansion during aging and response to demyelination
Poliani, P. L., Wang, Y., Fontana, E., Robinette, M. L., Yamanishi, Y., Gilfillan, S., & Colonna, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77983 · Cited by 525 · cited 2×
“Along with plaque compaction issues, microglia and macrophages lacking TREM2 have been shown to have decreased capacity to phagocytose and clear Ab, apoptotic cells, as well as other proteins and complexes [131,153,154].”
BackgroundLee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., & Lamb, B. T. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100265 · Cited by 522 · cited 1×
“[167] Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, et al.”
BackgroundSelf-citationInconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522 · cited 1×
“As stated previously, patients may exhibit Ab plaque pathology for up to or greater than a decade before any overt diagnosis of AD [35,36].”
BackgroundLeyns, C. E. G., Ulrich, J. D., Finn, M. B., Stewart, F. R., Koscal, L. J., Remolina Serrano, J., Robinson, G. O., Anderson, E., Colonna, M., & Holtzman, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710311114 · Cited by 517 · cited 2×
“The Holtzman group recently reported mitigated neuroinflammation, astrocytosis, and reduced neurodegeneration at advanced ages in the PS19 mouse model of tauopathy, an aggressive model of tauopathy harboring the FTD-associated P301S 4R familial tau mutation [157].”
BackgroundElevated circulating tumor necrosis factor levels in Alzheimer's disease
Fillit, H. M., Ding, W., Buée, L., Kalman, J., Altstiel, L. D., LAWLOR, B. A., & Wolf-Klein, G. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90490-k · Cited by 513 · cited 2×
“[192] Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, et al.”
BackgroundCX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival
Landsman, L., Bar‐On, L., Zernecke, A., Kim, K.-W., Krauthgamer, R., Shagdarsuren, E., Lira, S. A., Weissman, I. L., Weber, C., & Jung, S. (2008) · Blood · doi:10.1182/blood-2008-07-170787 · Cited by 505 · cited 1×
“[162] Landsman L, Bar-On L, Zernecke A, Kim K-W, Krauthgamer R,”
Cribbs, D. H., Berchtold, N. C., Perreau, V., Coleman, P. D., Rogers, J., Tenner, A. J., & Cotman, C. W. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-179 · Cited by 499 · cited 1×
“[51] Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, et al.”
BackgroundNSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
Insulin resistance associated to obesity: the link TNF-alpha
Nieto-Vázquez, I., Fernández‐Veledo, S., Kramer, D., Vila‐Bedmar, R., García‐Guerra, L., & Lorenzo, M. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802181047 · Cited by 493 · cited 2×
“[264] Nieto-Vazquez I, Fern andez-Veledo S, Kr€amer DK, Vila-Bedmar R, Garcia-Guerra L, LorenzoM.”
BackgroundThe role of interleukin-6 signaling in nervous tissue
Rothaug, M., Becker-Pauly, C., & Rose-John, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.018 · Cited by 491 · cited 2×
“[210] Rothaug M, Becker-Pauly C, Rose-John S.”
BackgroundCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Krabbe, G., Halle, A., Matyash, V., Rinnenthal, J. L., Eom, G. D., Bernhardt, U., Miller, K. R., Prokop, S., Kettenmann, H., & Heppner, F. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060921 · Cited by 478
Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease
Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467 · cited 2×
“A considerable literature has demonstrated that alterations in insulin levels and insulin receptor resistance (in particular in T2DM) within the brain impact survival and function of both neurons and glial cells that are dependent on intact insulin signaling [257,258].”
BackgroundImmune System Response in Alzheimer's Disease
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029863 · Cited by 463 · cited 1×
“[45] McGeer PL, Akiyama H, Itagaki S, McGeer EG.”
BackgroundLoss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460 · cited 1×
“[139] Paloneva J, Kestila M, Wu J, Salminen A, Bohling T, Ruotsalainen V, et al.”
BackgroundIMMUNOASSAY OF ENDOGENOUS PLASMA INSULIN IN MAN
Yalow, R. S., & Berson, S. A. (1996) · Obesity Research · doi:10.1002/j.1550-8528.1996.tb00274.x · Cited by 459 · cited 1×
“The defining characteristics of T2DM are impairments in insulin signaling and hyperglycemia [253,254], which appear to be the main contributing factors increasing the risk for AD.”
BackgroundDrug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459 · cited 2×
“Despite extensive and productive research investigating the mechanisms responsible for both core pathologies, as well as approaches aimed at the prevention of Ab plaques and NFT, there remains no treatment that effectively alters either pathology in clinical populations [34].”
BackgroundVisualization and characterization of interleukin 1 receptors in brain.
Farrar, W. L., Kilian, P. L., Ruff, M. R., Hill, J. M., & Pert, C. B. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.2.459 · Cited by 458 · cited 2×
“IL-1b-mediated actions are through binding to the IL-1 receptor, which is expressed throughout the brain but can be found in greatest concentration in the dentate gyrus and pyramidal cells in the hippocampus, which are key areas in the early development of AD pathology [205].”
BackgroundHaan, M. N. (1999) · JAMA · doi:10.1001/jama.282.1.40 · Cited by 457
Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease
Jay, T. R., Hirsch, A. M., Broihier, M. L., Miller, C. M., Neilson, L. E., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2110-16.2016 · Cited by 457 · cited 4×
“[146] Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, et al.”
BackgroundInfluentialSelf-citationQuintanilla, R. A., Orellana, D. I., González-Billault, C., & Maccioni, R. B. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.01.002 · Cited by 455 · cited 3×
“[95] Quintanilla RA, Orellana DI, Gonz alez-Billault C, Maccioni RB.”
BackgroundInfluentialNonsteroidal anti-inflammatory drugs in Alzheimer's disease
Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., & Brandt, J. (1995) · Neurology · doi:10.1212/wnl.45.1.51 · Cited by 446 · cited 1×
“[87] Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J.”
BackgroundProminent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 2×
“Early in AD pathogenesis, the mounted immune response results in clearance of Ab and has been demonstrated to exert positive effects on AD-related pathologies in animal models’ systems [77,119,120].”
BackgroundAlonso, A. D. C., Grundke-Iqbal, I., Barra, H. S., & Iqbal, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.298 · Cited by 437
Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31450 · Cited by 433
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432
Inflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427
Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease
Selkoe, D. J. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90008-a · Cited by 423
Glucose tolerance status and risk of dementia in the community
Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., Kanba, S., & Kiyohara, Y. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0435 · Cited by 421
Glial cytokines in Alzheimer's disease: Review and pathogenic implications
Mrak, R. E., Sheng, J. G., & Griffin, W. S. T. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90001-2 · Cited by 415
Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E., & Heuschling, P. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.02.003 · Cited by 411
Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease
McGeer, P. L., & Rogers, J. (1992) · Neurology · doi:10.1212/wnl.42.2.447 · Cited by 407 · cited 1×
“Unlike other risk factors and genetic causes of AD, neuroinflammation is not typically thought to be causal on its own but rather a result of one or more of the other AD pathologies or risk factors associated with AD and serves to increase the severity of the disease by exacerbating b-amyloid and tau pathologies [90,9…”
BackgroundHe, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390
Liao, Y.-F., Wang, B.-J., Cheng, H.-T., Kuo, L.-H., & Wolfe, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402034200 · Cited by 389
Interleukin‐1: A master regulator of neuroinflammation
Basu, A., Krady, J. K., & Levison, S. W. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20266 · Cited by 380 · cited 1×
“Pro-inflammatory signaling: IL-1b IL-1b has been described as a “master regulator” within the brain inflammatory cascade due to its integral role in regulating the expression of other proinflammatory cytokines, including TNF-a and IL-6, and that disruptions to IL-1b can delay the onset of neuroinflammation and neurode…”
BackgroundGarwood, C. J., Pooler, A. M., Atherton, J., Hanger, D. P., & Noble, W. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.50 · Cited by 379
Kloppenborg, R. P., van den Berg, E., Kappelle, L. J., & Biessels, G. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.049 · Cited by 368 · cited 1×
“[247] Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ.”
BackgroundYamamoto, M., Kiyota, T., Horiba, M., Buescher, J. L., Walsh, S. M., Gendelman, H. E., & Ikezu, T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060378 · Cited by 367
Nishiyori, A., Minami, M., Ohtani, Y., Takami, S., Yamamoto, J., Kawaguchi, N., Kume, T., Akaike, A., & Satoh, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00583-3 · Cited by 365
Cytokines, chemokines, and cytokine receptors in human microglia
Lee, Y. B., Nagai, A., & Kim, S. U. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10253 · Cited by 363
Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology
Guillot-Sestier, M.-V., Doty, K. R., Gate, D., Rodriguez, J., Leung, B. P., Rezai-Zadeh, K., & Town, T. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.068 · Cited by 363
Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease
Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & Felice, F. G. D. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.010 · Cited by 363 · cited 1×
“[58] Ferreira ST, Clarke JR, Bomfim TR, De Felice FG.”
BackgroundTau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359
Neuron–glia crosstalk in health and disease: fractalkine and CX 3 CR1 take centre stage
Sheridan, G. K., & Murphy, K. J. (2013) · Open Biology · doi:10.1098/rsob.130181 · Cited by 358 · cited 1×
“CX3CL1 binds to its obligate receptor, CX3CR1, on the surface of microglia [161].”
BackgroundInflammation and neurodegenerative diseases
Griffin, W. S. T. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.470s · Cited by 351
Raised Interleukin‐6 Levels in Obese Patients
Roytblat, L., Rachinsky, M., Fisher, A., Greemberg, L., Shapira, Y., Douvdevani, A., & Gelman, S. (2000) · Obesity Research · doi:10.1038/oby.2000.86 · Cited by 346 · cited 1×
“[262] Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y,”
BackgroundAssociation of Microglia with Amyloid Plaques in Brains of APP23 Transgenic Mice
Stalder, M., Phinney, A., Probst, A., Sommer, B., Staufenbiel, M., & Jucker, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65423-5 · Cited by 345 · cited 2×
“Activated microglia respond to Ab resulting in migration to the plaques and phagocytosis of Ab [108,112,113].”
BackgroundProduction and neuroprotective functions of fractalkine in the central nervous system
Mizuno, T., Kawanokuchi, J., Numata, K., & Suzumura, A. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02867-1 · Cited by 342
Microglial cells but not astrocytes undergo mitosis following rat facial nerve axotomy
Graeber, M. B., Tetzlaff, W., Streit, W. J., & Kreutzberg, G. W. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90585-x · Cited by 333 · cited 1×
“[110] Graeber MB, Tetzlaff W, Streit WJ, Kreutzberg GW.”
BackgroundKim, D.-G., Krenz, A., Toussaint, L. E., Maurer, K. J., Robinson, S.-A., Yan, A., Torres, L., & Bynoe, M. S. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0467-5 · Cited by 330 · cited 2×
“[274] Kim D-G, Krenz A, Toussaint LE, Maurer KJ, Robinson S-A, Yan A, et al.”
BackgroundChakrabarty, P., Jansen‐West, K., Beccard, A., Ceballos‐Diaz, C., Levites, Y., Verbeeck, C., Zubair, A. C., Dickson, D., Golde, T. E., & Das, P. (2010) · The FASEB Journal · doi:10.1096/fj.09-141754 · Cited by 328
Traumatic brain injury: A risk factor for Alzheimer's disease
Sivanandam, T. M., & Thakur, M. K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.02.013 · Cited by 326
Tucsek, Z., Tóth, P., Sosnowska, D., Gautam, T., Mitschelen, M. C., Koller, Á., Szalai, G., Sonntag, W. E., Ungvari, Z. I., & Csiszár, A. (2013) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt177 · Cited by 324 · cited 1×
“[272] Tucsek Z, Toth P, Sosnowska D, Gautam T, Mitschelen M, Koller A, et al.”
BackgroundAstrocytes are GABAergic cells that modulate microglial activity
Lee, M., Schwab, C., & McGeer, P. L. (2010) · Glia · doi:10.1002/glia.21087 · Cited by 321 · cited 5×
“By utilizing baclofen, a GABAB receptor agonist, intracellular inflammatory pathways were reduced by 40–60% [186].”
BackgroundInfluentialDAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features
Paloneva, J., Mandelin, J., Kiialainen, A., Böhling, T., Prudlo, J., Hakola, P., Haltia, M., Konttinen, Y. T., & Peltonen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030027 · Cited by 318 · cited 1×
“[137] Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, et al.”
BackgroundWu, Z., Guo, Z., Gearing, M., & Chen, G. (2014) · Nature Communications · doi:10.1038/ncomms5159 · Cited by 306
Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302
The role of TNF and its receptors in Alzheimer's disease
Perry, R. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00291-3 · Cited by 301 · cited 1×
“TNF-a increases vascular endothelial adhesion molecules, allowing leukocytes and immune cells to migrate into areas under duress [193].”
BackgroundCarson, M. J., Cameron Thrash, J., & Walter, B. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.004 · Cited by 299
Bemiller, S. M., McCray, T. J., Allan, K., Formica, S. V., Xu, G., Wilson, G., Kokiko-Cochran, O. N., Crish, S. D., Lasagna-Reeves, C. A., Ransohoff, R. M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0216-6 · Cited by 299 · cited 2×
“[156] Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, et al.”
BackgroundSelf-citationTREM2 regulates microglial cell activation in response to demyelination in vivo
Cantoni, C., Bollman, B., Licastro, D., Xie, M., Mikesell, R., Schmidt, R., Yuede, C. M., Galimberti, D., Olivecrona, G., Klein, R. S., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1388-1 · Cited by 296 · cited 2×
“Along with plaque compaction issues, microglia and macrophages lacking TREM2 have been shown to have decreased capacity to phagocytose and clear Ab, apoptotic cells, as well as other proteins and complexes [131,153,154].”
BackgroundAkama, K. T., & Van Eldik, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.7918 · Cited by 287
Diabetes Mellitus and Risk of Developing Alzheimer Disease
Akomolafe, A., Beiser, A., Meigs, J. B., Au, R., Green, R. C., Farrer, L. A., Wolf, P. A., & Seshadri, S. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1551 · Cited by 287
Implications of GABAergic Neurotransmission in Alzheimer’s Disease
Li, Y., Sun, H., Chen, Z., Xu, H., Bu, G., & Zheng, H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00031 · Cited by 282 · cited 1×
“[183] Li Y, SunH, Chen Z, XuH, BuG, ZhengH.”
The choreography of neuroinflammation in Huntington's disease
Crotti, A., & Glass, C. K. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.007 · Cited by 276
Diabetes Mellitus and the Risk of Alzheimer’s Disease: A Nationwide Population-Based Study
Huang, C., Chung, C., Leu, H., Lin, L., Chiu, C.-C., Hsu, C., Chiang, C.-H., Huang, P., Chen, T., Lin, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087095 · Cited by 272
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
Zotova, E., Nicoll, J. A. R., Kalaria, R. N., Holmes, C., & Boche, D. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt24 · Cited by 269 · cited 2×
“Unlike other risk factors and genetic causes of AD, neuroinflammation is not typically thought to be causal on its own but rather a result of one or more of the other AD pathologies or risk factors associated with AD and serves to increase the severity of the disease by exacerbating b-amyloid and tau pathologies [90,9…”
BackgroundCho, S.-H., Sun, B., Zhou, Y., Kauppinen, T. M., Halabisky, B., Wes, P., Ransohoff, R. M., & Gan, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.254268 · Cited by 268 · cited 2×
“Postmortem analyses show modest reductions of CX3CR1 and markedly lower levels of CX3CL1 in the hippocampus of AD brains compared with age-matched nondemented controls [178].”
BackgroundBlasko, I., Veerhuis, R., Stampfer-Kountchev, M., Saurwein-Teissl, M., Eikelenboom, P., & Grubeck-Loebenstein, B. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0321 · Cited by 258
Szczepanik, A. M. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00404-5 · Cited by 250
Faden, A. I., & Loane, D. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0319-5 · Cited by 245
GABAB Receptor Coupling to G-proteins and Ion Channels
Padgett, C. L., & Slesinger, P. A. (2010) · Advances in pharmacology · doi:10.1016/s1054-3589(10)58006-2 · Cited by 241 · cited 1×
“The released GABA binds to a fast-acting chloride channel (GABAA) resulting in rapid hyperpolarization or binding to a receptor coupled to a metabotropic G-protein coupled receptor (GABAB) that results in a slow inhibitory postsynaptic current (IPSC) [179].”
BackgroundThe Role of Immune and Inflammatory Mechanisms in ALS
McCombe, P., & Henderson, R. D. (2011) · Current Molecular Medicine · doi:10.2174/156652411795243450 · Cited by 238 · cited 2×
“CX3CR1-mediated neuronal signaling to microglia can be disrupted by replacing CX3CR1 with a green fluorescent protein (GFP) reporter gene that leads to systemic inflammation and exacerbated microglial neurotoxicity in a variety of animal models, including PD ALS [165,174].”
BackgroundDursun, E., Gezen-Ak, D., Hanağası, H., Bilgiç, B., Lohmann, E., Ertan, S., Atasoy, İ. L., Alaylıoğlu, M., Araz, Ö. S., Önal, B., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.014 · Cited by 237 · cited 6×
“IL-6 is elevated in the CSF and serum of AD patients and is considered a significant contributor to neuroinflammation observed in LOAD [212,213].”
BackgroundInfluentialInterleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife
Singh-Manoux, A., Dugravot, A., Brunner, E., Kumari, M., Shipley, M., Elbaz, A., & Kivimaki, M. (2014) · Neurology · doi:10.1212/wnl.0000000000000665 · Cited by 237 · cited 2×
“[211] Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A, et al.”
BackgroundBaik, S. H., Kang, S., Son, S. M., & Mook-Jung, I. (2016) · Glia · doi:10.1002/glia.23074 · Cited by 234
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival
Lionakis, M. S., Swamydas, M., Fischer, B. G., Plantinga, T. S., Johnson, M. D., Jaeger, M., Green, N. M., Masedunskas, A., Weigert, R., Mikelis, C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci71307 · Cited by 230 · cited 1×
“[163] Lionakis MS, Swamydas M, Fischer BG, Plantinga TS, JohnsonMD,”
BackgroundRegulation of chemokine receptor expression in human microglia and astrocytes
Flynn, G., Maru, S., Loughlin, J., Romero, I. A., & Male, D. K. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00009-2 · Cited by 229 · cited 1×
“[105] Flynn G,Maru S, Loughlin J, Romero IA,Male D.”
TREM2 and the neuroimmunology of Alzheimer's disease
Hickman, S. E., & El Khoury, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.021 · Cited by 221
Tamboli, I. Y., Barth, E., Christian, L., Siepmann, M., Kumar, S., Singh, S., Tolksdorf, K., Heneka, M. T., Lütjohann, D., Wunderlich, P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149468 · Cited by 220
Increased Serum IL-1β Level in Alzheimer’s Disease and Mild Cognitive Impairment
Forlenza, O. V., Diniz, B. S., Talib, L. L., Mendonça, V. A., Ojopi, E. P. B., Gattaz, W. F., & Teixeira, A. L. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000255051 · Cited by 218
Microglia express GABA(B) receptors to modulate interleukin release
Kuhn, S. A., van Landeghem, F. K. H., Zacharias, R., Färber, K., Rappert, A., Pavlovic, S., Hoffmann, A., Nolte, C., & Kettenmann, H. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.10.023 · Cited by 218
Huell, M., Strauss, S., Volk, B., Berger, M., & Bauer, J. (1995) · Acta Neuropathologica · doi:10.1007/bf00571510 · Cited by 214
Modulating neurotoxicity through CX3CL1/CX3CR1 signaling
Limatola, C., & Ransohoff, R. M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00229 · Cited by 210 · cited 1×
“CX3CL1 is a pleiotropic protein involved in the abatement of microglia under basal conditions but also regulates microglial activity by influencing migration and proliferation in injury conditions [171].”
BackgroundDavidson, T. L., Monnot, A. D., Neal, A. U., Martin, A., Horton, J., & Zheng, W. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.05.015 · Cited by 202
Yates, S. L., Burgess, L. H., Kocsis‐Angle, J., Antal, J. M., Dority, M. D., Embury, P. B., Piotrkowski, A. M., & Brunden, K. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741017.x · Cited by 202
van Himbergen, T. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.670 · Cited by 202
Neuroinflammatory phenotype in early Alzheimer's disease
Sudduth, T. L., Schmitt, F. A., Nelson, P. T., & Wilcock, D. M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.012 · Cited by 201 · cited 1×
“[53] Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM.”
BackgroundNolte, C., Möller, T., Walter, T., & Kettenmann, H. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00106-6 · Cited by 199 · cited 1×
“[101] Nolte C, Moller T, Walter T, Kettenmann H.”
BackgroundMiguel-Álvarez, M., Santos‐Lozano, A., Sanchis‐Gomar, F., Fiuza‐Luces, C., Pareja-Galeano, H., Garatachea, N., & Lucía, A. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0239-z · Cited by 197
Neurological consequences of traumatic brain injuries in sports
Ling, H., Hardy, J., & Zetterberg, H. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.03.012 · Cited by 197
Research works printed but not linked: 3
- Alzheimer's Impact Movement, 2017, Alzheimer's Disease Caregivers Factsheet
- 10.1186/1750-1326-9-20 · DOI · Paper page
- 10.1186/s13024-017-0216-6 · DOI · Paper page
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
“Direct microglial effects on neuron viability—Activated microglia can directly secrete toxic proinflammatory cytokines (Colonna and Butovsky, 2017; Kinney et al., 2018) or secrete indirect mediators that stimulate astrocytes to secrete a neurotoxic substance (Liddelow et al.”
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“Numerous cytokines and chemokines have been shown to contribute to the pathogenesis of neurodegenerative diseases as summarized by the recent reviews.(9,253,412) In addition to cytokines and chemokines, bioactive lipids also play crucial role during all phases of the innate immune responses.”
BackgroundRecent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
“Due to the dysregulation of GABAergic mechanism in AD, the inhibitory role of GABA on activated microglia is also lost which further contributes to the release of pro-inflammatory cytokines [17].”
BackgroundOxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease
Bai, R., Guo, J., Ye, X.-Y., Xie, Y., & Xie, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101619 · Cited by 813
Metadata
- Authors
- Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T.
- Affiliations
- University of Nevada, Las Vegas (US)
- Indiana University Indianapolis (US)
- Department of Psychology University of Nevada Las Vegas Las Vegas NV USA
- Corresponding author
- Kinney, Jefferson W.
- ORCID
- Lamb, Bruce T.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 575-590
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC6214864
- OpenAlex
- W2889787710
- Cited by
- 2,253
- References
- 283
- Citations by year
- 2026: 187 · 2025: 395 · 2024: 401 · 2023: 353 · 2022: 326 · 2021: 286 · 2020: 226 · 2019: 76 · 2018: 1
- FWCI
- 13.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by-nd)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by-nc-nd)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, neuroinflammation, microglia, amyloid plaques, neurofibrillary tangles, tau pathology, cytokines, risk factors, neurodegeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
